Clinical Trial Update: A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib with durvalumab for metastatic soft tissue sarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Durvalumab (durvalumab)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Yonsei University | Conditions: Sarcoma | Phase 2 | Status: COMPLETED